Patents by Inventor Ron Diskin

Ron Diskin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against infectious pathogens and method for production thereof
    Publication number: 20240075139
    Abstract: The present invention relates to a method for obtaining monoclonal human antibodies directed against an infectious pathogen, monoclonal human antibodies or binding fragments thereof which are directed against an infectious pathogen as obtained by the method of the invention, a pharmaceutical composition comprising such monoclonal human antibodies, a kit comprising such antibodies, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament and in the treatment or prevention of a disease caused by the infectious pathogen.
    Type: Application
    Filed: October 7, 2020
    Publication date: March 7, 2024
    Inventors: Florian Klein, Matthias Zehner, Stefanie Ehrhardt, Ron Diskin
  • Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof
    Publication number: 20230365661
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: February 22, 2023
    Publication date: November 16, 2023
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120
    Publication number: 20230192823
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Application
    Filed: October 13, 2022
    Publication date: June 22, 2023
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Human immunodeficiency virus neutralizing antibodies and methods of use thereof
    Patent number: 11634478
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: April 25, 2023
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
    Patent number: 11472868
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: October 18, 2022
    Assignees: CALIFORNIA INSTITUTE OF TECHNOLOGY, THE ROCKEFELLER UNIVERSITY
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • ANTIBODIES TARGETING HIV ESCAPE MUTANTS
    Publication number: 20220169707
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Application
    Filed: October 13, 2021
    Publication date: June 2, 2022
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Ron Diskin, Anthony P. West, Michel Nussenzweig, Pamela J. Bjorkman
  • HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants
    Patent number: 11149081
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: October 19, 2021
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210230254
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: January 11, 2021
    Publication date: July 29, 2021
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Human immunodeficiency virus neutralizing antibodies and methods of use thereof
    Patent number: 10889633
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 12, 2021
    Assignees: The Rockefeller University, California Institute of Technoloqy
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • IMMUNOTHERAPY AGAINST TRANSFERRIN RECEPTOR 1 (TFR1)-TROPIC ARENAVIRUSES
    Publication number: 20200392203
    Abstract: A composition of matter comprising an isolated soluble polypeptide comprising an amino acid sequence of a Transferrin receptor protein 1 (TfR1) apical domain is disclosed, the soluble polypeptide being capable of binding an Arenavirus. A fusion protein comprising an amino acid sequence of a TfR1 apical domain and an amino acid sequence of IgG Fc, the fusion protein capable of binding an Arenavirus, is also disclosed.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 17, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Ron DISKIN, Hadas COHEN-DVASHI
  • HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120
    Publication number: 20200165325
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Application
    Filed: February 10, 2020
    Publication date: May 28, 2020
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120
    Patent number: 10590187
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 17, 2020
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120
    Publication number: 20180237506
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 23, 2018
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • ANTIBODIES TARGETING HIV ESCAPE MUTANTS
    Publication number: 20180230203
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Application
    Filed: December 7, 2017
    Publication date: August 16, 2018
    Inventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
  • Human Immunodeficiency Virus Neutralizing Antibodies and Methods of Use Thereof
    Publication number: 20180079800
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 22, 2018
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
    Patent number: 9890207
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: February 13, 2018
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Antibodies targeting HIV escape mutants
    Patent number: 9879068
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 30, 2018
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
  • Human immunodeficiency virus neutralizing antibodies and methods of use thereof
    Patent number: 9783594
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: October 10, 2017
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
    Patent number: 9493549
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution in the heavy chain at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4 and an amino acid substitution in the light chain, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 15, 2016
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140328862
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: May 17, 2012
    Publication date: November 6, 2014
    Applicants: THE ROCKEFELLER UNIVERSITY, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin